| Literature DB >> 28694960 |
Altug Yucekul1, Deniz Ozdil2,3, Nuri Hunkar Kutlu2, Esra Erdemli4, Halil Murat Aydin5, Mahmut Nedim Doral1.
Abstract
Cartilage defects are a source of pain, immobility, and reduced quality of life for patients who have acquired these defects through injury, wear, or disease. The avascular nature of cartilage tissue adds to the complexity of cartilage tissue repair or regeneration efforts. The known limitations of using autografts, allografts, or xenografts further add to this complexity. Autologous chondrocyte implantation or matrix-assisted chondrocyte implantation techniques attempt to introduce cultured cartilage cells to defect areas in the patient, but clinical success with these are impeded by the avascularity of cartilage tissue. Biodegradable, synthetic scaffolds capable of supporting local cells and overcoming the issue of poor vascularization would bypass the issues of current cartilage treatment options. In this study, we propose a biodegradable, tri-layered (poly(glycolic acid) mesh/poly(l-lactic acid)-colorant tidemark layer/collagen Type I and ceramic microparticle-coated poly(l-lactic acid)-poly(ϵ-caprolactone) monolith) osteochondral plug indicated for the repair of cartilage defects. The porous plug allows the continual transport of bone marrow constituents from the subchondral layer to the cartilage defect site for a more effective repair of the area. Assessment of the in vivo performance of the implant was conducted in an ovine model (n = 13). In addition to a control group (no implant), one group received the implant alone (Group A), while another group was supplemented with hyaluronic acid (0.8 mL at 10 mg/mL solution; Group B). Analyses performed on specimens from the in vivo study revealed that the implant achieves cartilage formation within 6 months. No adverse tissue reactions or other complications were reported. Our findings indicate that the porous biocompatible implant seems to be a promising treatment option for the cartilage repair.Entities:
Keywords: Osteochondral repair; beta-tricalcium phosphate; cartilage repair; hyaluronic acid; poly-l-lactic acid; polyglycolic acid
Year: 2017 PMID: 28694960 PMCID: PMC5496685 DOI: 10.1177/2041731417697500
Source DB: PubMed Journal: J Tissue Eng ISSN: 2041-7314 Impact factor: 7.813
The current approaches used in the treatment of cartilage and osteochondral defects.
| Method | Notes |
|---|---|
| Lavage/arthroscopic cleaning with NaCl/Ringer’s solution | Alleviate pain. The effects are only temporary. No healing achieved in later stages. |
| Debridement[ | Symptomatic relief. Not stimulate chondrogenesis or repair. |
| Abrasion arthroplasty and drilling[ | Achieve formation of fibrous, hyaline-like cartilage. Drilling is more effective. No full healing. |
| Osteotomy[ | Involves the manual realignment of cartilage surface by interrupting the bone at a distance from the cartilage lesions. |
| Total knee replacement procedures[ | Performed in more aged patients as the life time of the prosthetics is limited by its loosening with time, and a significant amount of bone loss and pain is associated with prosthetic joints. |
| Microfracture[ | Involves the stimulation of repair using microfractures through which the bone marrow is drawn from the subchondral bone. The fibrous and mechanically weak tissue which forms in this way provides only a temporary solution. |
| Autologous chondrocyte transplantation (ACT)[ | Approximately 10–12 million cells can be implanted into a 10-cm2 defect area. Rehabilitation in the postoperative period is of importance. Complications include the postoperative problems that may form with arthrotomy, the inability to successfully suture periosteal tissue to defect sites, and the delayed hypertrophic response of the body. |
| Osteochondral transplantation or mosaicplasty[ | Involves transplanting healthy tissues containing the required cells from a donor site to areas where they are needed. Disadvantages include donor site morbidity, abrasion against surfaces opposite to the graft, and damage to chondrocytes within donor and recipient regions. |
| Scaffolds/matrices (polymeric or composite), MACI[ | Cells proliferated on the matrix and then this structure is delivered to the defect site. Disadvantages include the loss of phenotypic features of chondrocytes and the inability to homogeneously distribute these cells. |
| Stem cells delivered within 3D matrices | The key criteria include biocompatibility, porosity, biodegradability, and the ability to prevent phenotypic losses in cells and enabling their uniform distribution. Poor cell distribution and mechanical strength are the two main limiting factors for the uptake of such matrices. |
MACI: matrix-assisted chondrocyte implantation; 3D: three-dimensional.
Figure 1.(a) Micro-CT images of the osteochondral plugs and (b) a cross-sectional view revealing the layered structure.
Figure 2.Arthroscopic image taken from Merinos sheep with composite scaffold implantation (Group A) sacrificed at 3 months.
Figure 3.A macroscopic analysis image of the defect sites at 6 months in (a) the control, (b) Group A, and (c) Group B animals, respectively, and (d) the bone side.
Figure 4.(a) Representative arthroscopic images of knee of the control group, (b) defects with osteochondral plugs, and (c) defects with the osteochondral plug + hyaluronic acid taken at 6 months.
Figure 5.Representative MRI images of (a) the control group, (b) Group A, and (c) Group B.
Figure 6.In Mallory trichrome staining: (a) control group, (b) Group A, and (c) Group B.
f: fibrous connective tissue; ch: cartilage; S: scaffold; *: cavitation; arrows: vessels.
Figure 7.In Mallory trichrome staining: (a) control group, showing only activating cells (↑) going toward fibrous connective tissue; (b) Group A, cartilage tissue which invades fibrocartilage tissue (↑); and (c) Group B, fibrocartilage tissue cells are seen (↑).
Semi-quantitative scoring of the cartilage repair.
| Parameter | Control | Group A | Group B |
|---|---|---|---|
| I | 50% (2) | 75% (1) | 100% (0) |
| II | Not close (2) | Almost (1) | Yes (1) |
| III | Significantly reduced staining (2) | Reduced staining (2) | Normal (1) |
| IV | Some fibrocartilage but mostly nonchondrocytic cells (3) | Mostly fibrocartilage (2) | Mostly hyaline and fibrocartilage (1) |
Scale parameters (I) percent filling of the defect, (II) reconstitution of the osteochondral junction, (III) matrix staining, and (IV) cell morphology with score range starting from 0 (best).
Figure 8.(a–c) Expression of collagen Type II. Tissues were stained using the NorthernLights™ 557-conjugated anti-goat IgG secondary antibody (yellow, Catalog #ab34712) and counterstained with DAPI (blue). Scale bar: 100 µm; (d–f) Aggrecan immunostaining. Cells were stained using the NorthernLights 557-conjugated anti-goat IgG secondary antibody (yellow, Catalog #ab3773) and counterstained with DAPI (blue). Scale bar: 100 µm.